ANTIMICROBIAL AGENTS CHEMOTHERAPY, Oct. 2008, p. 3710â€“3717                                                                   Vol. 52,  10
0066-4804/08/$08.00â«¹0 doi:10.1128/AAC.00364-08
Copyright Â© 2008, American Society Microbiology. Rights Reserved.



    Glycogen Synthase Kinase 3 Potential Drug Target African
                       Trypanosomiasis TherapyäŒ¤
  Kayode K. Ojo,1 J. Robert Gillespie,1 Aaron J. Riechers,1 Alberto J. Napuli,2 Christophe L. M. J. Verlinde,2
        Frederick S. Buckner,1 Michael H. Gelb,3 Mathias M. Domostoj,4 Susan J. Wells,4
               Alexander Scheer,4 Timothy N. C. Wells,4 Wesley C. Van Voorhis1*
  Division Allergy Infectious Diseases, Department Medicine,1 Department Biochemistry,2 Department Chemistry,3
                  University Washington, Seattle, Washington 98195, Merck-Serono Geneva Research Centre,
                        Merck-Serono International S  Chemin des Mines 9, Geneva CH-1202, Switzerland4
                           Received 16 March 2008/Returned modification 26 2008/Accepted 10 July 2008

            Development safe, effective, inexpensive therapy African trypanosomiasis urgent priority.
          study, evaluated validity Trypanosoma brucei glycogen synthase kinase 3 (GSK-3) potential
          drug target. Interference RNA GSK-3 homologues bloodstream-form T. brucei
          parasites led growth arrest altered parasite morphology, demonstrating requirement cell
          survival. growth arrest RNA interference appeared profound T. brucei GSK-3
          â€œshortâ€? (Tb10.161.3140) T. brucei GSK-3 â€œlongâ€? (Tb927.7.2420), focused T. brucei GSK-3 short
          studies. T. brucei GSK-3 short N-terminal maltose-binding protein fusion cloned,
          expressed, purified functional form. potency GSK-3-focused inhibitor library           recombinant enzyme T. brucei GSK-3 short, bloodstream-form parasites, evaluated           aim determining compounds inhibit enzyme activity block parasitesâ€™ growth           proliferation. compounds active cell, excellent correlation activity
          inhibiting T. brucei GSK-3 short enzyme inhibition T. brucei growth.  reasonable
          genetic chemical validation GSK-3 short drug target T. brucei. Finally, selective inhibition           required therapy targeting GSK-3 enzyme, molecular model T. brucei GSK-3 short
          enzyme suggests compounds selectively inhibit T. brucei GSK-3 short human GSK-3 enzymes
          


   vector-borne parasitic disease African trypanosomiasis,                  protein degradation machinery. kinases ex-
caused members Trypanosoma brucei complex,                       amined physiological relevance phosphoryla- health threat. estimated 300,000 500,000                  tion activities organisms, glycogen synthase kinase
humans sub-Saharan African infected. disease                   3 (GSK-3) essential fundamental
left inadequately treated, fatal outcome (9).               cellular processes (22, 30).
infection established, safe effective therapy critically                 Far simply important glycogen synthesis, important, difficult achieve. Despite                    activity GSK-3 recognized key mammalian cell
critical need, available therapies satis-                 signaling pathways cellular physiological events
factory rising level resistance available                  (26). GSK-3 targeted treatment drugs, long period treatment required achieve cure,                 diseases, diabetes mellitus Alzheimerâ€™s dementia, unacceptable severe adverse effects                       enzyme amenable selective
associated current therapies (9). urgent priority                 targeting small-molecule drugs (22). GSK-3 iso-
identify validate new targets development safe,                  forms human cells, GSK-3â?£ GSK-3â?¤. GSK-3â?£ effective, inexpensive therapeutic alternatives.                            GSK-3â?¤ isoforms rarely diverge outside N- C-terminal
   Recent advances area parasite genomics bio-                    regions. ATP binding site GSK-3, chemical investigation physiologically important                      GSK-3 inhibitors bind, appears single amino
zymes necessary parasiteâ€™s survival identified pro-                acid difference (Glu196 GSK-3â?£, Asp133 GSK-3â?¤), tein kinases potential drug targets treatments                        inhibitors target isoforms. GSK-3 generally requires
trypanosomatid diseases (3, 14, 23). Protein kinases play                    substrate prephosphorylated priming kinase (6, 7,
important role cell survival phosphorylating regulat-                 10, 32) (Fig. 1), leading role signaling cascades. GSK-3
ing activities cell, including protein synthesis, gene              regulated autophosphorylation phosphorylation expression, subcellular localization proteins,                   enzymes.
                                                                                   orthologs exhibit high degree sequence
                                                                                similarity catalytic domains (7, 22), exists
  * Corresponding author. Mailing address: Division Allergy              evolutionary differences human parasite homo-
Infectious Diseases, Department Medicine, Box 357185, 1959 NE
Pacific St., Seattle, WA 98195-7185. Phone: (206) 543-2447. Fax: (206)
                                                                                logues sufficient allow design parasite-
685-8681. E-mail: wesley@u.washington.edu.                                      specific inhibitors. Compounds inhibit T. brucei GSK-3
  äŒ¤
    Published ahead print 21 July 2008.                                   activity host GSK-3 required therapy 
                                                                         3710
 VOL. 52, 2008                                                              GSK-3: DRUG TARGET AFRICAN TRYPANOSOMIASIS                                        3711

                                                                                     knock longer isoform. regions T. brucei GSK-3 short                                                                                      long gene-coding sequences selected RNAi plasmid construction 
                                                                                     termined using RNA target selection program RNAit (29), ensure                                                                                      significant sequence homology genes genome.
                                                                                     sequences T. brucei genomic DNA used construction RNAi
                                                                                     plasmids taken GeneDB accession nos. Tb10.61.3140 T. brucei
                                                                                     GSK-3 short (nucleotides 176 578 construct 1 665 1056 construct
   FIG. 1. Enzymatic action GSK-3. GSK-3 substrates,                    2) Tb927.7.2420 T. brucei long (nucleotides 159 531). nucleotide (priming) kinase places phosphate (PO3) serine               bases primer pairs (primer pairs 1 2, 3 4, 5 6 [Table
threonine (S/T) residue separated amino acids (X)                    1]) amplified T. brucei 927 genomic DNA. resultant amplicons
carboxy direction target S/T residues. GSK-3 phosphorylates                  ligated use TA cloning vector p2T7TABlue  gift D.
target S/T groups. Occasionally, GSK-3 shown phosphor-                   Horn, London School Hygiene Tropical Medicine) (2), se-
ylate nonprimed peptide substrates shown autophos-                   quences confirmed nucleotide sequence analysis inserts. phorylate GSK-3 S/T tyrosine (10, 32).                                         constructs linearized NotI restriction enzyme (New England Bio-
                                                                                     labs, Ipswich, MA). T. brucei bloodstream-form (BSF) parasites (provided  G.
                                                                                     Cross, Rockefeller University) expressing T7 RNA polymerase Tet
                                                                                     repressor single selection marker (SM), G418 resistance, cultured
pregnant women infants, GSK-3 regulates proteins                         HMI-9 medium 10  heat-inactivated fetal bovine serum G418 2.5
critical development, wnt gene product.                           â?®g/ml 37Â°C 5  CO2 atmosphere (15). micrograms T. brucei GSK-3  optimization selectivity drug candidates                         linearized p2T7TABlue electroporated mid-log-phase T. brucei
parasite kinases issue highly conserved                        (2.5 â«» 107) suspended 500 â?®l cytomix (120 mM KCl, 0.15 mM CaCl2, 10
                                                                                     mM K2HPO4-KH2PO4, pH 7.6, 25 mM HEPES, 2 mM disodium EDTA, 5 mM
amino acids protein conformation catalytic domains
                                                                                     MgCl2). Electroporation 4-mm gap cuvettes 1.6 kV 24 â?€, (5, 18, 25, 26). Understanding differences substrate                      described previously (33). cells resuspended HMI-9 medium sup-
binding properties dimensional structures                           plemented 2.5 â?®g/ml hygromycin 2.5 â?®g/ml G418. Stable individual
tween mammalian parasite GSK-3 enzymes important                              clones selected 5 7 days transfection. Selected cultures diluted optimization selected target inhibitors drug                       1 â«» 105 cells/ml induced express double-stranded RNA addition 1
                                                                                     â?®g/ml tetracycline. Growth measured cultures passed daily 1:10 velopment (6, 18).
                                                                                     1:20 dilution monitored ATPLite luminescence ATP detection
   report, RNA interference (RNAi)                             assay (catalog  6016941; Perkin-Elmer, Waltham, MA). Cell growth
assay chemical validation T. brucei GSK-3 poten-                       monitored 7 days.
tial drug target treatment African sleeping sickness.                        Northern analysis. RNA isolated induced noninduced cultures
Inhibitor-target interactions, expressed calculated inter-                    48 h growth RNeasy kit (Qiagen, Valencia, CA). 16 â?®g
                                                                                     total RNA electrophoresed formaldehyde gel blotted stan-
action energy, predicted improved using
                                                                                     dard procedures (4). RNA membrane analyzed 32P-labeled modeling software detect binding pockets                             DNA probe complementary GSK-3 mRNA region contained present T. brucei GSK-3 absent human ho-                             RNAi constructs. probe amplified genomic DNA primers 3
molog enzyme (18).                                                            4 GSK-3 short version 1, primers 1 2 GSK-3 short version 2,                                                                                      primers 7 8 GSK-3 long (Table 1).
                                                                                        DNA-DNA hybridization. Genomic DNA isolated T. brucei brucei
                         MATERIALS METHODS                                       427 lysis TELT buffer (50 mM Tris HCl, pH 8.0, 62.5 mM EDTA, 2.5 M
  Bioinformatics. T. brucei orthologs human GSK-3â?£ (UniProt P49840)           LiCl, 49  [vol/vol] Triton X-100), followed phenol-chloroform extraction
human GSK-3â?¤ (UniProt P49841) identified T. brucei genome             (20), subjected double restriction endonuclease digests. Enzymes using BLASTP tool website GeneDB (www. Genedb.org). Amino acid            regions outside gene cut 1,000 bp outside sequence identity values determined using ALIGN tool (24)         genes picked. restricted fragments run 1.0  agarose gel,
Biology Workbench (version 3.2) website (http://segtool.sdsc.edu/CGI/BW.cgi).        visualized staining ethidium bromide, subsequently blotted   RNAi. T. brucei GSK-3 homologs, encode long isoform (T.            nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, 
brucei GSK-3 long) short isoform (T. brucei GSK-3 short) enzyme,        gland) capillary transfer. membrane probed appropriately
                                                                                     32
respectively, targets knockdown experiment. RNAi constructs            P-radiolabeled RNAi region GSK-3 short version 1 gene amplified knock short gene, RNAi construct           primer pairs 1 2 (Table 1).



                                                           TABLE 1. Oligonucleotide primers used
       Primer use                 ORF position                Primer designation                                      Sequence (5â¬˜â€“3â¬˜)

RNAi
 1                                          176â€“578              GSKshort1Fwd                        CTGGATCCACCGAGAGTTGCAAATTATG
 2                                                               GSKshort1Rev                        AAGGATCCTAGTAACGCGAGCAAATGTA
 3                                          665â€“1056             GSKshort2Fwd                        GTGGATCCTTCTTGGTGAACCGATATTC
 4                                                               GSKshort2Rev                        TTGGATCCCTTCTTCAGCAGATACTCCC
 5                                          159â€“531              GSKLongFwd                          CCATGCGAGCAAGTGAGGTATG
 6                                                               GSKLongRev                          GGCACTGGGATCAGAAGCGAAG
 7                                        1013â€“1422              GSKLongprobe1a                      CATCTGAGCGGGAACTCTTCG
 8                                                               GSKLongprobe2a                      CAGCCACGGTGGTAAAATCTC

GSK-3 protein expression
 9                                            1â€“1059             T. brucei GSKLICFwd                 CTCACCACCACCACCACCATATGTCGCTCAACC
                                                                                                      TTACCGATGC
  10                                                             T. brucei GSKLICRev                 ATCCTATCTTACTCACTTACTTCTTCAGCAGAT
                                                                                                      ACTCCCGC
        Used probes Northern blot analysis T. brucei GSK-3 long.
 3712         OJO ET AL.                                                                                                   ANTIMICROB. AGENTS CHEMOTHER.


  TABLE 2. Comparison amino acid sequence identities       human orthologs GSK-3 T. brucei GSK-3
                   long GSK-3 short
                                                Identitya
        Enzyme               Human             T. brucei          T. brucei
                             GSK-3â?¤           GSK-3 long         GSK-3 short

Human GSK-3â?£              67.4 (1eâ«º177)     29.7 (2.2 eâ«º66)     35.6 (2.7eâ«º82)
Human GSK-3â?¤                                33.1 (1.0eâ«º71)      40.9 (9.1eâ«º89)
T. brucei GSK-3 long                                            30.6 (4.6eâ«º66)
        smallest sum probability BLASTP search shown parentheses.



   PCR ligase-independent cloning. Regions T. brucei GSK-3 short
gene open reading frame (ORF) amplified T. brucei brucei 427              FIG. 3. Southern blot T. brucei genomic DNA T. brucei
genomic DNA primers T. brucei GSKLICFwd, T. brucei GSKLICRev             GSK-3 short-specific probe. Genomic T. brucei brucei 427 SM DNA
(primers 9 10, respectively, Table 1). primer probe sequences used    digested, blotted, probed RNAi region GSK-3 study listed Table 1. PCR product cloned          short 1 (S1) verify single band corresponding T.
maltose-binding protein (MBP)â€“AVA0421 fusion vector. MBP-AVA0421             brucei GSK-3 short gene hybridizes T. brucei genome. ligase-independent cloning vector expresses proteins N-terminal    predicted restriction digest sizes follows: BamHI-PstI, 1,702 bp; MBPâ€“3C cleavage siteâ€“ORF fusion. MBP-AVA0421 generated               BamHI-AvaI, 2,214 bp; NcoI-PstI, 2,655 bp; NcoI-AvaI, 3,167 bp.



                                                                                  AVA0421 ligating PCR-amplified MBP sequence MBPâ€“
                                                                                  BG1861 NdeI KpnI restrictions sites (1). inserts                                                                                   vector double digested NruI PmeI joined ligase-
                                                                                  independent cloning, described previously (21).
                                                                                     Expression purification T. brucei GSK-3 short version. expression
                                                                                  recombinant protein automatically induced Escherichia coli
                                                                                  BL21(DE5)* (Invitrogen, Carlsbad, CA) ZY5052 medium supplemented                                                                                   100 â?®g/ml ampicillin growth 24 h 20Â°C agitation 200 rpm. Cells
                                                                                  harvested centrifugation stored â«º80Â°C flash
                                                                                  frozen liquid nitrogen. frozen cells resuspended disrupted                                                                                   sonication 200 ml lysis buffer containing 25 mM HEPES (pH 7.25), 500 mM
                                                                                  NaCl, 5  glycerol, 2 mM dithiothreitol (DTT) (standard buffer) 10 mg
                                                                                  lysozyme 20 mM imidazole. cell debris clarified centrifugation,
                                                                                  target protein purified clarified cell lysate binding                                                                                   nitrilotriacetic acid nickel resins (Qiagen) equilibrated standard buffer.                                                                                   recombinant T. brucei GSK-3 short protein eluted 250 mM imidazole plus
                                                                                  1 mM DTT dialyzed standard buffer 1 mM DTT                                                                                   resolved size-exclusion gel chromatography (Superdex 75 26/60; GE Bio-
                                                                                  sciences, Piscataway, NJ). Pure fractions collected single peak analyzed
                                                                                  sodium dodecyl sulfate-polyacrylamide gel electrophoresis Bio-Rad gel
                                                                                  code blue staining  Fig. 4). enzymes stored â«º20Â°C 50 
                                                                                  glycerolâ€“12.5 â?®M HEPES pH 7.5â€“250 â?®M NaClâ€“0.5 â?®M DTTâ€“0.0125  sodium
                                                                                  azideâ€“1â«» protease inhibitor (Roche, Indianapolis, .
                                                                                     Chemical inhibitors. GW8510 (Sigma Chemical , St. Louis, MO) (16),
                                                                                  SU9516 (Sigma) (22), SB-415286 (Biomol, Plymouth Meeting, PA) (22), cyclin-
                                                                                  dependent kinase (CDK) 1 2 inhibitor III (Calbiochem, San Diego, CA) (8),
                                                                                  2-cyanoethyl alsterpaullone (Calbiochem) (17)  Table 3), 43 com-
                                                                                  mercially available protein kinase inhibitors (Sigma, Biomol, Calbiochem)
                                                                                  included study. addition, 255-compound GSK-3-focused library
                                                                                  collection obtained Merck-Serono (Geneva, Switzerland) evalu-
                                                                                  ated. Merck-Serono GSK-3 inhibitors 2 -2-[4-tert-butylthia-
                                                                                  zol-2(3H)-ylidene]-2-(2-aminopyrimidin-4-yl) acetonitrile core structure    FIG. 2. RNAi T. brucei GSK-3 homologs.   Growth T.                   modifications  R1 structures Table 4).
brucei BSF number days tetracycline addition (day 0). T.             Activity assay. Enzyme activity measured scintillation proximity assay
brucei brucei strain 427 SM cells transfected plasmids,           (SPA) streptavidin-coated beads, [â?¥-33P]ATP (Amersham Biosciences tetracycline administration, leads induction double-               Corp., Piscataway, NJ), biotinylated peptide substrate [BioGSP-2; peptide
stranded RNA, resulting RNAi inhibition target gene expression.             sequence biotin-C6-Tyr-Arg-Arg-Ala-Ala-Val-Pro-Pro-Ser-Pro-Ser-Leu-Ser-Ar homologs GSK-3, T. brucei GSK-3 long T. brucei GSK-3                  g Ser-Ser-Pro Gln-Ser(PO3H2)-Glu-Asp-Glu-Glu-Glu; American Pep-
short  different constructs T. brucei GSK-3 short), sepa-             tide Company, , Sunnyvale, CA]. filtration assay used measure rately targeted, SM cells served plasmid controls. ad-             specific activity GSK-3 Kms ATP peptide substrate
dition tetracycline (â«¹), dramatic growth inhibition compared              (BioGSP-2), measured determining level incorporation tetracycline control (â«º) occurred long            â?¥-33P peptide subsequent binding P-81 filter (Whatman, short T. brucei GSK-3 homolog targeted.   North-                Florhan Park, NJ). assays performed buffered solution containing
ern blots showing reduction mRNA levels (Gene) T.                  25 mM Tris-HCl (pH 7.5), 10 mM MgCl2 ä¡  6H2O, 5 mM DTT, 0.1 mg/ml bovine
brucei GSK-3 short (S1 S2) T. brucei GSK-3 long (L) tran-                 serum albumin, 2 U/ml heparin incubation 30Â°C. filtration
scripts tetracycline induction (lanes â«¹) tetracycline induc-          assay reaction volume 50 â?®l contained 1.2 â?®M BioGSP-2, serially diluted
tion (lanes â«º). result tubulin mRNA control (Tub) differed              enzyme, unlabeled (1.2 â?®M) â?¥-33P-labeled ATP (4 nM); reac-
little RNAi induction tetracycline.                                    tion mixture incubated 60 min. reactions stopped 100 â?®l
 VOL. 52, 2008                                                              GSK-3: DRUG TARGET AFRICAN TRYPANOSOMIASIS                                       3713

                                                                                    10  trifluoroacetic acid 37.5 mM EDTA 750 â?®M unlabeled ATP.                                                                                     content reaction mixture spotted P-81 filters, filters                                                                                     washed times 2.5  phosphoric acid. SPA used screen                                                                                     inhibitors determine 50  inhibitory concentrations (IC50s) 303 
                                                                                    hibitors T. brucei GSK-3 short version Km determined ATP
                                                                                    peptide. mixture used SPA included 20 ng (46.8 nM)                                                                                     enzyme, 2.4 â?®M peptide substrate, 4.5 â?®M unlabeled ATP, 4 nM â?¥-33P-
                                                                                    labeled ATP. reaction mixture incubated 30 min. Quantitative
                                                                                    measurement levels phosphate incorporation binding BioGSP-2
                                                                                    T. brucei GSK-3 short enzyme 100 â?®l 20 mg/ml strepta-
                                                                                    vidin-coated SPA beads 37.5 mM EDTAâ€“75 â?®M unlabeled ATP.                                                                                     assay, human GSK-3â?¤ (Upstate Cell Signaling Solutions, Temecula, CA)                                                                                     assay buffer used positive negative controls, respectively. emis-
                                                                                    sion light SPA bead simulation reaction measured counts                                                                                     minute Chameleon 425-104 multilabel plate scintillation counter (Hidex;
                                                                                    Oy, Turku, Finland).
                                                                                       Parasite cultures vitro compound screening assays. BSF T. brucei
                                                                                    brucei strain 427 cultured HMI-9 medium supplemented 10 
                                                                                    heat-deactivated fetal bovine serum, 1  penicillin, streptomycin 37Â°C
                                                                                    5  CO2 atmosphere, described previously (15). vitro suscep-
                                                                                    tibilities parasites compounds tested 96 plates    FIG. 4. Purity recombinant T. brucei GSK-3 short produced E.               initial inoculum size 1 â«» 105 trypomastigotes  Compound stock
coli. enzyme purified metal affinity chromatography, fol-                solutions prepared dimethyl sulfoxide 10 20 mM diluted lowed size-exclusion chromatography. lanes representing 25                 HMI-9 medium 20 â?®M. added plates serial
â?®g protein fractions size exclusion chromatography (frac-
                                                                                    dilutions final volume 200 â?®l  growth triplicate cultures
tions 1 3, respectively) pooled make working batch
                                                                                    quantitated 48 h addition Alamar blue (Alamar Bio- enzyme study shown. purity judged                                                                                     sciences, Sacramento, CA) (28). Pentamidine isethionate (Aventis, Dagen-
greater 98 .


                          TABLE 3. Commercial kinase inhibitorsa activity GSK enzyme T. brucei BSFs
                                                                                                                        IC50 (nM)                                                                                                                                                                EC50b
            Compound                                                    Structure                                       T. brucei GSK
                                                                                                                                                               (nM)
                                                                                                                           enzyme




GW8510                                                                                                                           1                              119




CDK-1 -2 inhibitor III                                                                                                     13                                 20




2-Cyanoethyl alsterpaullone                                                                                                   336                               150




SU9516                                                                                                                        352                               180




SB-415286                                                                                                                   1,000                               740



        inhibitors selected panel 48 kinase inhibitors.
  b
      EC50s determined T. brucei BSF growth assay.
 3714       OJO ET AL.                                                                                                        ANTIMICROB. AGENTS CHEMOTHER.

ham, United Kingdom) included assay positive control.              TABLE 4. GSK-3-focused inhibitorsa Merck-Serono effective concentration caused 50  growth inhibition (EC50) cal-                activities GSK-3 enzyme T. brucei BSFs
culated nonlinear regression analysis Prism software (Graphpad Soft-
ware,  La Jolla, CA).                                                                                  R1 core structure
   Modeling T. brucei GSK-3 homology inhibitor docking. Protein                                                             IC50 (nM)                                                                                       Compound                                                                   ED50
                                                                                                                                       T. brucei GSK
Data Bank contains 14 structures human GSK, variations                                                                                    (nM)b
                                                                                                                                          enzyme
motion hinge domain N- C-terminal lobes enzyme. modeling dimensional structure T. brucei GSK-3 short
version (Protein Data Bank accession  1R0E), human GSK-3 complexed                  1                                                  4                  50 3-indolyl-4-arylmaleimide inhibitor ultimately chosen template 
cause resulting model led best quantitative structure-activity relation-
ships Merck-Serono inhibitors 2 -2-[4-tert-butylthiazol-              2                                                30                   65
2(3H)-ylidene]-2-(2-aminopyrimidin-4-yl) acetonitrile core structure. Creation protein model Homology module INSIGHTII program                         3                                                46                  200
(Accelrys Software, , San Diego CA) straightforward, insertions deletions occurred binding site. Molecular docking inhibitors performed Metropolis Monte Carlo procedures FLO/QXP program                     4                                                22                  410
(19). Inhibitors treated fully flexible, chains amino
acid residues binding site.
                                                                                            5                                                30                  458


                                  RESULTS                                                   6                                               168                  705
   Sequence analysis RNAi. GSK-3-encoding genes T. brucei genome BLAST homology                                                                                                                              inhibitors selected panel 255 GSK-3â?¤ inhibitors.
searches: long version (Tb927.7.2420, encoded pre-                           b
                                                                                           EC50s determined T. brucei BSF growth assay.
dicted 501-amino-acid protein) short version (Tb10.61.
3140, encoded predicted 352-amino-acid protein). Ho-
mology comparisons did reveal homolog equivalent GSK-3â?£ GSK-3â?¤ mammalian form                                 MBP (Fig. 4), non-MBP-fused T. brucei
(Table 2), T. brucei GSK-3 long T. brucei GSK-3                          GSK-3 short enzyme insoluble E. coli. Km short homologous human GSK-3â?¤ human                               enzyme substrate ATP determined 4.5 â?®M, GSK-3â?£. knockdown T. brucei GSK-3 short long                                Km phosphorylated peptide (GSP-2) 2.4 â?®M.
mRNA accomplished overexpressing double-stranded                               specific activity purified T. brucei GSK-3 short
RNA mammalian BSFs T. brucei. RNAi constructs                               enzyme 1,000 U/mg  1 U defined separately tested knock expression T.                         incorporation 1 nM phosphate 1.2 â?®M GSP-2 brucei GSK-3 short gene. 48 h, Northern analysis demon-                            min 30Â°C final ATP concentration 1.2 â?®M), strated 65  mRNA reduction T. brucei GSK-3 short                                comparable value 922 U/mg cited commercially
construct 1 76  mRNA reduction T. brucei GSK-3                              available human GSK-3â?¤ (lot 28407U; Upstate Cell Signaling
short construct 2 (Fig. 2). reduction T. brucei                     Solutions).
GSK-3 short mRNA, induction double-stranded RNA                                   Activities kinase inhibitors T. brucei GSK-3 short
led striking inhibition cell proliferation (Fig. 2).                     construct T. brucei BSF parasites. Screening 48 com-
duction T. brucei GSK-3 long RNAi construct yielded                         mercially available protein kinase inhibitors revealed 82  reduction mRNA gene (Fig. 2),                             GW8510 (Table 3) activities 1 nM (IC50) T.
inhibition growth complete produced                          brucei GSK-3 short enzyme 100 nM (EC50) T. brucei GSK-3 short constructs (Fig. 2).                         BSFs T. brucei. identified compounds pronounced growth inhibition RNAi directed                            (Table 3) activities enzyme, T. brucei GSK-3 short, chose focus work                          inhibiting additional targets T. brucei cells, suggested
T. brucei GSK-3 short enzyme.                                                         comparatively low EC50s comparison IC50s.
   Southern blot analysis. Hybridization Southern blot                           screen 255 compounds known activity membrane radiolabeled GSK-3 short-specific probe                           human GSK-3â?¤ (Merck-Serono), observed correlation sequence used RNAi) revealed single band                              enzyme cellular activity, supports hybridized double restriction enzyme digests rule                        chemical validation T. brucei GSK-3 drug target (ex- possible target effect RNAi sequence.                       amples shown Table 4). excellent correlation 
case, molecular weight hybridizing band pre-                           tween enzyme inhibition cell growth inhibition dem-
dicted T. brucei GSK-3 short genomic sequence (Fig.                          onstrated compounds series inhibited T.
3). presence single band digest mo-                          brucei GSK-3 enzyme T. brucei BSF growth. 
lecular weight predicted T. brucei GSK-3 short indicates                          search required establish â€œhitâ€? compounds identified sequence complementary RNAi                             kill T. brucei cells specifically inhibiting GSK-3 short, segment used genome T. brucei, gene                       chemical data support validation GSK-3 short drug
T. brucei GSK-3 short.                                                                target T. brucei.
   Expression highly active recombinant T. brucei GSK-3                               Model T. brucei GSK-3 Merck-Serono inhibitors. short enzyme. recombinant T. brucei GSK-3 short                               homology model T. brucei GSK-3 short constructed struct produced Escherichia coli C-terminal fusion                        basis crystal structure human GSK-3â?¤ enzyme  VOL. 52, 2008                                                   GSK-3: DRUG TARGET AFRICAN TRYPANOSOMIASIS                          3715




   FIG. 5. Correlation experimental (Exp) predicted
(Pred) binding energies (Ebind) use T. brucei GSK-3 short
homology model. R2 0.85; F 23.3, indicates linear relationship highly significant 99.0  level.


complex inhibitor. Subsequently, Merck-Serono
inhibitors listed Table 4 docked validate model determination structure-activity relationship. linear
regression predicted binding energies exper-
imental energies derived IC50s showed excellent
correlation (R2 â«½ 0.85; n â«½ 6; F â«½ 23.3, indicates                FIG. 6. Model binding mode Merck-Serono inhibitor 2
                                                                        (yellow) T. brucei GSK-3 short  Pymol; DeLano Scientific
significance level 99.0 ) (Fig. 5). predicted binding            LLC, San Carlos, CA; http://www.pymol.org).
mode 30 nM Merck-Serono inhibitor 2 shown Fig. 6. features double hydrogen bond recognition pattern typical kinase inhibitors involves 2-amino-
pyrimidinyl group inhibitor consecutive hydrogen           causes specific effect T. brucei GSK-3 short gene
bond donor acceptor protein backbone.              expression. suggests growth-inhibitory effect
hydrophobic contacts present thiazolyl              T. brucei GSK-3 short RNAi occurs independently T.
Cys-170, Phe-31 originating glycine-rich        brucei GSK-3 long inhibition T. brucei GSK-3 short
loop characteristic kinases; nitrile â€œgatekeeperâ€?       long nonoverlapping functions com-
residue Met-101; pyrimidinyl Leu-159. N-                plemented 
methyl-piperidinyl makes hydrogen bond carbonyl                Second, anti-BSF cellular activities activities
Pro-105 enveloped Phe-103 Arg-110,                T. brucei GSK-3 short enzyme series kinase salt bridge Glu-106. comparison            inhibitors directed GSK-3 correlated  human enzyme structure model T. brucei                exclude possibility compounds inhibit targets zyme structure, predicted specificities           cell GSK-3 exert effects GSK-3 kinase inhibitors differences          additive actions. instance, known GSK-3
seven residues binding site (Table 5).                           inhibitors inhibit CDK-1 -2 (11, 31), active
                                                                        sites similar active site GSK-3 (27). inhibi-
                                                                        tion CDKs shown arrest growth T. brucei
                          DISCUSSION
                                                                        (12, 13, 31). Recombinant CDK homolog enzymes    paper, report genetic chemical validation data        currently available T. brucei difficulty support hypothesis T. brucei GSK-3 short drug        heterologous expression proteins;  target T. brucei.  RNAi experiments targeting T. brucei       unable test cross-activities compounds GSK-3 short demonstrated dramatic inhibition growth              CDKs. likely kinase inhibitors act targets T. brucei BSFs. likely RNAi construct inhibits        T. brucei GSK-3 short inhibit BSF cell growth, target T. brucei GSK-3 short gene probing              protein kinase inhibitors effectively impaired cell growth DNA fragment used RNAi Southern                   little activity T. brucei GSK-3 short. 
analysis showed single hybridizing band  sepa-           strong correlation T. brucei GSK-3 short
rate digests) molecular weight expected T.             enzyme activity BSF cell proliferation inhibition.  brucei GSK-3 short gene.  insufficient nucleo-           chemical genetic evidence favors T. brucei GSK-3 short tide identity cross hybridization Southern analysis. Fur-        good target drugs, activities
thermore, nucleotide sequence T. brucei GSK-3                T. brucei.
short RNAi construct 47  identity correspond-              ability selectively target T. brucei GSK-3 enzymes
ing region T. brucei GSK-3 long, stretches nucle-         mammalian GSK-3 orthologs important otide identity longer 11 bases, indicating unlikely     avoid toxicity caused effects cell signaling cell T. brucei GSK-3 short RNAi affect T. brucei              cycle regulation. Human GSK-3â?¤ T. brucei GSK-3 short
GSK-3 long expression.  likely RNAi           41  identical,  possible selec-
 3716          OJO ET AL.                                                                                                                                ANTIMICROB. AGENTS CHEMOTHER.


         TABLE 5. Comparison GSK-3 binding site residuesa                                                         M. E. Dumont, E. M. Phizicky, E. J. Grayhack. 2004. facile method                                                                                                                      high-throughput expression protein pairs. Mol. Cell. Proteomics 3:934â€“
T. brucei                                                                                        Human               938.
                                                                                                                2.   Alibu, V. P., L. Storm, S. Haile, C. Clayton, D. Horn. 2005. doubly
V25 ................................................................................................... V61          inducible RNA interference rapid RNAi plasmid construc-
A26.................................................................................................... I62          tion Trypanosoma brucei. Mol. Biochem. Parasitol. 139:75â€“82.
G27 ................................................................................................... G63     3.   Allocco, J. J., R. Donald, T. Zhong,  Lee, Y. S. Tang, R. C. Hendrickson,
Q28b .................................................................................................. N64b         P. Liberator, B. Nare. 2006. Inhibitors casein kinase 1 block G29 ................................................................................................... G65          growth Leishmania major promastigotes vitro. Int. J. Parasitol. 36:
T30 .................................................................................................... S66         1249â€“1259.
F31 .................................................................................................... F67    4.   Barbu, V., F. Dautry. 1989. Northern blot normalization 28S
                                                                                                                     rRNA oligonucleotide probe. Nucleic Acids Res. 17:7115.
V34 ................................................................................................... V70
                                                                                                                5.   Copeland, R. , D. L. Pompliano, T. D. Meek. 2006. Drug-target
L36 .................................................................................................... Q72         residence time implications lead optimization. Nat. Rev. Drug
A47 ................................................................................................... A83          Discov. 5:730â€“739.
K49 ................................................................................................... K85     6.   Dajani, R., E. Fraser, S. M. Roe, N. Young, V. Good, T. C. Dale, L. H.
E 61................................................................................................... E97          Pearl. 2001. Crystal structure glycogen synthase kinase 3 beta: structural
M65................................................................................................... M101          basis phosphate-primed substrate specificity autoinhibition. Cell
V77 ................................................................................................... V110         105:721â€“732.
M101................................................................................................. L132      7.   Droucheau, E.,  Primot, V. Thomas, D. Mattei, M. Knockaert, C. Rich-
E102b ................................................................................................ D133b         ardson, P. Sallicandro, P. Alano,  Jafarshad, B. Baratte, C. Kunick, D.
                                                                                                                     Parzy, L. Pearl, C. Doerig, L. Meijer. 2004. Plasmodium falciparum
F103 .................................................................................................. Y134         glycogen synthase kinase-3: molecular model, expression, intracellular local-
V104b ................................................................................................ V135b         isation selective inhibitors. Biochim. Biophys. Acta 1697:181â€“196.
P105 .................................................................................................. P136    8.   Eswaran, J., W. H. Lee, J. E. Debreczeni, P. Filippakopoulos,  Turnbull, O.
E106.................................................................................................. E137          Fedorov, S. W. Deacon, J. R. Peterson, S. Knapp. 2007. Crystal struc-
T107.................................................................................................. T138          tures p21-activated kinases PAK4, PAK5, PAK6 reveal catalytic
H109 ................................................................................................. Y140          domain plasticity active group II PAKs. Structure 15:201â€“213.
R110 ................................................................................................. R141     9.   Fairlamb,  H. 2003. Chemotherapy human African trypanosomiasis:
K154 ................................................................................................. K183          current future prospects. Trends Parasitol. 19:488â€“494.
                                                                                                               10.   Frame, S., P. Cohen. 2001. GSK3 takes centre stage 20 years
H156 ................................................................................................. Q185          discovery. Biochem. J. 359:1â€“16.
N157 ................................................................................................. N186    11.   Grant, K. M., M. H. Dunion, V. Yardley,  L. Skaltsounis, D. Marko, G.
L159.................................................................................................. L188          Eisenbrand, S. L. Croft, L. Meijer, J. C. Mottram. 2004. Inhibitors C170.................................................................................................. C199          Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library
D171 ................................................................................................. D200          screen antileishmanial activity. Antimicrob. Agents Chemother.
                                                                                                                     48:3033â€“3042.
        different pairs shown boldface.                                                               12.   Hammarton, T. C., J. Clark, F. Douglas, M. Boshart, J. C. Mottram.
  b
      backbone binding site.                                                                      2003. Stage-specific differences cell cycle control Trypanosoma brucei
                                                                                                                     revealed RNA interference mitotic cyclin. J. Biol. Chem. 278:22877â€“
                                                                                                                     22886.
                                                                                                               13.   Hammarton, T. C., M. Engstler, J. C. Mottram. 2004. Trypanosoma
tive inhibitors T. brucei GSK-3 short                                                         brucei cyclin, CYC2, required cell cycle progression G1 phase molecular modeling studies differences active                                                        maintenance procyclic form cell morphology. J. Biol. Chem.
                                                                                                                     279:24757â€“24764.
sites able translated development                                                14.   Hammarton, T. C., J. C. Mottram, C. Doerig. 2003. cell cycle of selective inhibitors. example potential selectivity                                                    parasitic protozoa: potential chemotherapeutic exploitation. Prog. Cell study interactions Merck-Serono                                                       Cycle Res. 5:91â€“101.
                                                                                                               15.   Hirumi, H., K. Hirumi. 1989. Continuous cultivation Trypanosoma
inhibitors predicted Met-101 T. brucei GSK-3                                                       brucei blood stream forms medium containing low concentration short, Leu human GSK-3â?¤. pursuing                                                               serum protein feeder cell layers. J. Parasitol. 75:985â€“989.
determination crystallographic structures T. brucei                                                  16.   Johnson, K., L. Liu, N. Majdzadeh, C. Chavez, P. C. Chin, B. Morrison, L.
                                                                                                                     Wang, J. Park, P. Chugh, H. M. Chen, S. R. Dâ€™Mello. 2005. Inhibition GSK-3 short complexed inhibitors; difficult                                                     neuronal apoptosis cyclin-dependent kinase inhibitor GW8510: iden- cleave MBP T. brucei GSK-3 short, separate nonphos-                                                          tification 3â¬˜ substituted indolones scaffold development                                                                                                                      neuroprotective drugs. J. Neurochem. 93:538â€“548.
phorylated phosphorylated proteins, sufficient
                                                                                                               17.   Kunick, C.,  Zeng, R. Gussio, D. Zaharevitz, M. Leost, F. Totzke, C.
protein crystallization trials. Future studies include                                                      Scha Â¨chtele, M. H. G. Kubbutat, L. Meijer, T. Lemcke. 2005. Structure-
continued attempts solve dimensional structure                                                       aided optimization kinase inhibitors derived alsterpaullone. Chem-
                                                                                                                     biochem 6:541â€“549. perform high-throughput screening inhibitors                                                 18.   Liao, J. J. 2007. Molecular recognition protein kinase binding pockets T. brucei GSK-3 short human GSK-3â?¤                                                               design potent selective kinase inhibitors. J. Med. Chem. 50:409â€“424.
compounds selectivity T. brucei GSK-3 short.                                                     19.   McMartin, C., R. S. Bohacek. 1997. QXP: powerful, rapid                                                                                                                      algorithms structure-based drug design. J. Comput. Aided Mol. Des.
                                                                                                                     11:333â€“344.
                                 ACKNOWLEDGMENTS                                                               20.   Medina-Acosta, E., G.  Cross. 1993. Rapid isolation DNA                                                                                                                      trypanosomatid protozoa using simple â€˜mini-prepâ€™ procedure. Mol. Bio-
  acknowledge key collaborations initiated Solomon Nwaka                                                   chem. Parasitol. 59:327â€“329. UNICEF/UNDP/World Bank Special Programme                                                         21.   Mehlin, C., E. Boni, F. S. Buckner, L. Engel, T. Feist, M. H. Gelb, L. Haji,
search Training Tropical Diseases, continues advise                                                 D. Kim, C. Liu, N. Mueller, P. J. Myler, J. T. Reddy, J. N. Sampson, E. project. acknowledge support Wim Hol                                                   Subramanian, W. C. Van Voorhis, E. Worthey, F. Zucker, W. G. Hol.
entire Medical Structural Genomics Pathogenic Protozoa group,                                                     2006. Heterologous expression proteins Plasmodium falciparum: initiated cloning characterization T. brucei GSK-3                                                    results 1000 genes. Mol. Biochem. Parasitol. 148:144â€“160.
short.                                                                                                         22.   Meijer, L., M. Flajolet, P. Greengard. 2004. Pharmacological inhibitors
  Funding study UNICEF/UNDP/World Bank/                                                            glycogen synthase kinase 3. Trends Pharmacol. Sci. 25:471â€“480.
                                                                                                               23.   Naula, C., M. Parsons, J. C. Mottram. 2005. Protein kinases drug Special Programme Research Training Tropical Dis-                                                     targets trypanosomes Leishmania. Biochim. Biophys. Acta 1754:151â€“
eases unrestricted grant Merck-Serono.                                                                   159.
                                                                                                               24.   Pearson, W. R., D. J. Lipman. 1988. Improved tools biological
                                           REFERENCES                                                                sequence comparison. Proc. Natl. Acad. Sci. USA 85:2444â€“2448.
 1. Alexandrov, , M. Vignali, D. J. LaCount, E. Quartley, C. Vries, D.                                 25.   Pink, R.,  Hudson, M.  Mouries, M. Bendig. 2005. Opportunities     Rosa, J. Babulski, S. F. Mitchell, L. W. Schoenfeld, S. Fields, W. G. Hol,                                       challenges antiparasitic drug discovery. Nat. Rev. Drug Discov. 4:727â€“740.
 VOL. 52, 2008                                                               GSK-3: DRUG TARGET AFRICAN TRYPANOSOMIASIS                                     3717

26. Plyte, S. E., K. Hughes, E. Nikolakaki, B. J. Pulverer, J. R. Woodgett.         synthase kinase-3 beta intact cells serine 9 phosphorylation. Biochem.
    1992. Glycogen synthase kinase-3: functions oncogenesis develop-             J. 303:701â€“704.
    ment. Biochim. Biophys. Acta 1114:147â€“162.                                      31. Tu, X., C. C. Wang. 2005. Pairwise knockdowns cdc2-related kinases
27. Polychronopoulos